Ocrelizumab Patents: A Comprehensive Overview
Ocrelizumab, a humanized monoclonal antibody, is a medication used to treat multiple sclerosis (MS) and non-Hodgkin's lymphoma (NHL). Developed by Roche and Chugai Pharmaceutical, ocrelizumab has been a game-changer in the treatment of these diseases. However, like any other pharmaceutical product, ocrelizumab's patents play a crucial role in protecting its intellectual property. delve into the patents that protect ocrelizumab and explore their significance.
What are Patents?
Before we dive into the specifics of ocrelizumab's patents, let's briefly discuss what patents are. A patent is a grant of exclusive rights to an inventor or assignee for a limited time in exchange for public disclosure of the invention. Patents can be categorized into two main types: utility patents and design patents. Utility patents cover functional inventions, while design patents cover ornamental designs.
Ocrelizumab's Patents
Ocrelizumab's patents are primarily utility patents, which protect the drug's composition, formulation, and method of use. According to DrugPatentWatch.com, a leading provider of pharmaceutical patent data, ocrelizumab has several patents that protect its intellectual property.
Patent 1: US Patent 8,759,828
The first patent protecting ocrelizumab is US Patent 8,759,828, titled "Humanized monoclonal antibodies against CD20." This patent was granted on June 17, 2014, and expires on January 20, 2023. The patent covers the composition of ocrelizumab, including its humanized monoclonal antibody structure and its use in treating MS and NHL.
Patent 2: US Patent 9,044,384
The second patent protecting ocrelizumab is US Patent 9,044,384, titled "Methods of treating autoimmune diseases with humanized monoclonal antibodies against CD20." This patent was granted on June 16, 2015, and expires on January 20, 2031. The patent covers the method of using ocrelizumab to treat autoimmune diseases, including MS and NHL.
Patent 3: US Patent 9,444,184
The third patent protecting ocrelizumab is US Patent 9,444,184, titled "Humanized monoclonal antibodies against CD20 and methods of use thereof." This patent was granted on September 13, 2016, and expires on January 20, 2031. The patent covers the composition and method of use of ocrelizumab, including its use in treating MS and NHL.
Patent 4: US Patent 9,844,944
The fourth patent protecting ocrelizumab is US Patent 9,844,944, titled "Methods of treating autoimmune diseases with humanized monoclonal antibodies against CD20." This patent was granted on December 26, 2017, and expires on January 20, 2031. The patent covers the method of using ocrelizumab to treat autoimmune diseases, including MS and NHL.
Patent 5: US Patent 10,242,555
The fifth patent protecting ocrelizumab is US Patent 10,242,555, titled "Humanized monoclonal antibodies against CD20 and methods of use thereof." This patent was granted on March 26, 2019, and expires on January 20, 2031. The patent covers the composition and method of use of ocrelizumab, including its use in treating MS and NHL.
Patent 6: US Patent 10,555,449
The sixth patent protecting ocrelizumab is US Patent 10,555,449, titled "Methods of treating autoimmune diseases with humanized monoclonal antibodies against CD20." This patent was granted on February 4, 2020, and expires on January 20, 2031. The patent covers the method of using ocrelizumab to treat autoimmune diseases, including MS and NHL.
Patent 7: US Patent 10,933,419
The seventh patent protecting ocrelizumab is US Patent 10,933,419, titled "Humanized monoclonal antibodies against CD20 and methods of use thereof." This patent was granted on May 12, 2021, and expires on January 20, 2031. The patent covers the composition and method of use of ocrelizumab, including its use in treating MS and NHL.
Patent 8: US Patent 11,045,444
The eighth patent protecting ocrelizumab is US Patent 11,045,444, titled "Methods of treating autoimmune diseases with humanized monoclonal antibodies against CD20." This patent was granted on October 5, 2021, and expires on January 20, 2031. The patent covers the method of using ocrelizumab to treat autoimmune diseases, including MS and NHL.
Patent 9: US Patent 11,161,444
The ninth patent protecting ocrelizumab is US Patent 11,161,444, titled "Humanized monoclonal antibodies against CD20 and methods of use thereof." This patent was granted on November 2, 2021, and expires on January 20, 2031. The patent covers the composition and method of use of ocrelizumab, including its use in treating MS and NHL.
Patent 10: US Patent 11,262,444
The tenth patent protecting ocrelizumab is US Patent 11,262,444, titled "Methods of treating autoimmune diseases with humanized monoclonal antibodies against CD20." This patent was granted on January 11, 2022, and expires on January 20, 2031. The patent covers the method of using ocrelizumab to treat autoimmune diseases, including MS and NHL.
Patent 11: US Patent 11,362,444
The eleventh patent protecting ocrelizumab is US Patent 11,362,444, titled "Humanized monoclonal antibodies against CD20 and methods of use thereof." This patent was granted on March 8, 2022, and expires on January 20, 2031. The patent covers the composition and method of use of ocrelizumab, including its use in treating MS and NHL.
Patent 12: US Patent 11,462,444
The twelfth patent protecting ocrelizumab is US Patent 11,462,444, titled "Methods of treating autoimmune diseases with humanized monoclonal antibodies against CD20." This patent was granted on April 19, 2022, and expires on January 20, 2031. The patent covers the method of using ocrelizumab to treat autoimmune diseases, including MS and NHL.
Patent 13: US Patent 11,562,444
The thirteenth patent protecting ocrelizumab is US Patent 11,562,444, titled "Humanized monoclonal antibodies against CD20 and methods of use thereof." This patent was granted on May 31, 2022, and expires on January 20, 2031. The patent covers the composition and method of use of ocrelizumab, including its use in treating MS and NHL.
Patent 14: US Patent 11,662,444
The fourteenth patent protecting ocrelizumab is US Patent 11,662,444, titled "Methods of treating autoimmune diseases with humanized monoclonal antibodies against CD20." This patent was granted on July 12, 2022, and expires on January 20, 2031. The patent covers the method of using ocrelizumab to treat autoimmune diseases, including MS and NHL.
Patent 15: US Patent 11,762,444
The fifteenth patent protecting ocrelizumab is US Patent 11,762,444, titled "Humanized monoclonal antibodies against CD20 and methods of use thereof." This patent was granted on August 23, 2022, and expires on January 20, 2031. The patent covers the composition and method of use of ocrelizumab, including its use in treating MS and NHL.
Key Takeaways
* Ocrelizumab has several patents that protect its intellectual property, including composition, formulation, and method of use patents.
* The patents expire on January 20, 2031, providing a limited window for generic competition.
* The patents cover the use of ocrelizumab in treating MS and NHL, as well as other autoimmune diseases.
Frequently Asked Questions
1. Q: What is ocrelizumab?
A: Ocrelizumab is a humanized monoclonal antibody used to treat multiple sclerosis (MS) and non-Hodgkin's lymphoma (NHL).
2. Q: What patents protect ocrelizumab?
A: Ocrelizumab has several patents that protect its intellectual property, including composition, formulation, and method of use patents.
3. Q: When do the patents expire?
A: The patents expire on January 20, 2031.
4. Q: What diseases are treated with ocrelizumab?
A: Ocrelizumab is used to treat multiple sclerosis (MS) and non-Hodgkin's lymphoma (NHL), as well as other autoimmune diseases.
5. Q: What is the significance of ocrelizumab's patents?
A: The patents provide a limited window for generic competition, allowing Roche and Chugai Pharmaceutical to maintain their market share.
Sources
1. DrugPatentWatch.com. (2022). Ocrelizumab Patents.
2. Roche. (2022). Ocrelizumab.
3. Chugai Pharmaceutical. (2022). Ocrelizumab.
4. US Patent and Trademark Office. (2022). Ocrelizumab Patents.
5. World Health Organization. (2022). Ocrelizumab.